A Phase 1, Open-Label, Non-randomized, Dose-Escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 24 Sep 2018
Price : $35 *
At a glance
- Drugs TAS 114 (Primary) ; Capecitabine
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical
- 17 Sep 2018 Status changed from active, no longer recruiting to completed.
- 13 Apr 2018 According to a Taiho Oncology media release, data from this trial is being presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR).
- 12 Jun 2017 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History